DrugPatentWatch Database Preview
VIIBRYD Drug Profile
Which patents cover Viibryd, and when can generic versions of Viibryd launch?
Viibryd is a drug marketed by Allergan Sales Llc and is included in one NDA. There are five patents protecting this drug and one Paragraph IV challenge.
This drug has ninety-two patent family members in thirty-two countries.
The generic ingredient in VIIBRYD is vilazodone hydrochloride. There are fourteen drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the vilazodone hydrochloride profile page.
Summary for VIIBRYD
| International Patents: | 92 |
| US Patents: | 5 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 2 |
| Bulk Api Vendors: | 66 |
| Clinical Trials: | 16 |
| Patent Applications: | 35 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for VIIBRYD |
| Drug Sales Revenues: | Drug sales revenues for VIIBRYD |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for VIIBRYD |
| DailyMed Link: | VIIBRYD at DailyMed |
Generic Entry Opportunity Date for VIIBRYD
Generic Entry Date for VIIBRYD*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for VIIBRYD
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Forest Laboratories | Phase 1 |
| New York State Psychiatric Institute | Phase 4 |
| Forest Laboratories | Phase 3 |
Recent Litigation for VIIBRYD
Identify potential future generic entrants
District Court Litigation
| Case Name | Date |
|---|---|
| Forest Laboratories LLC v. InvaGen Pharmaceuticals Inc. | 2015-11-23 |
| Forest Laboratories LLC v. InvaGen Pharmaceuticals Inc. | 2015-03-30 |
| Forest Laboratories LLC v. Accord Healthcare Inc. | 2015-03-27 |
PTAB Litigation
| Petitioner | Date |
|---|---|
| Argentum Pharmaceuticals LLC | 2018-01-05 |
Synonyms for VIIBRYD
| 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride |
| 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)piperazine hydrochloride |
| 1-[4-(5-cyanoindol-3-yl)butyl]4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride |
| 163521-08-2 |
| 2-Benzofurancarboxamide, 5-(4-(4-(5-cyano-1H-indol-3-yl)butyl)-1-piperazinyl)-, hydrochloride (1:1) |
| 2-Benzofurancarboxamide, 5-[4-[4-(5-cyano-1H-indol-3-yl)butyl]-1-piperazinyl]-, hydrochloride |
| 2794AH |
| 4-(2-carbamoyl-1-benzofuran-5-yl)-1-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-ium chloride |
| 5-(4-(4-(5-Cyano-1H-indol-3-yl)butyl)piperazin-1-yl)benzofuran-2-carboxamide hydrochloride |
| 5-(4-(4-(5-Cyano-1H-indol-3-yl)butyl)piperazin-1-yl)benzofuran-2-carboxamide monohydrochloride |
| 5-(4-[4-(5-cyano-3-indolyl)-butyl]-1-piperazinyl)-benzofuran-2carboxamide hydrochloride |
| 5-[4-[4-(5-Cyano-1H-indol-3-yl)butyl]-1-piperazinyl]-2-benzofurancarboxamide hydrochloride |
| 5-[4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl]-1-benzofuran-2-carboxamide hydrochloride |
| 5-[4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl]-1-benzofuran-2-carboxamide;hydrochloride |
| 5-[4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl]benzofuran-2-carboxamide hydrochloride |
| 5-[4-[4-(5-Cyanoindol-3-yl)butyl]piperazin-1-yl]benzofuran-2-carboxamide hydrochloride |
| 5-{4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl}-1-benzofuran-2-carboxamide hydrochloride |
| 521V128 |
| A3919 |
| AB0000947 |
| AC-25885 |
| AC1OCFA0 |
| AK161007 |
| AKOS024464039 |
| AN-5344 |
| API0009252 |
| AX8294006 |
| BCP11496 |
| C26H27N5O2.ClH |
| CCG-213313 |
| CHEBI:70705 |
| CHEMBL1615374 |
| CS-0549 |
| D09699 |
| EBD2199528 |
| EMD 68 843 |
| EMD 68843 |
| EMD-68-843 |
| EMD-68843 |
| EMD68843 |
| HY-14261 |
| J-525160 |
| KB-81444 |
| KS-00000SKE |
| LS-34922 |
| MolPort-028-744-909 |
| RL02096 |
| RL02097 |
| RPZBRGFNBNQSOP-UHFFFAOYSA-N |
| s4259 |
| SB 659746A |
| SB-659746-A |
| SB-659746A |
| SB659746-A |
| SB659746A |
| SCHEMBL867358 |
| ST24050347 |
| SW219887-1 |
| U8HTX2GK8J |
| UNII-U8HTX2GK8J |
| Viibryd (TN) |
| Vilazodone (Hydrochloride) |
| Vilazodone HCl |
| Vilazodone hydrochloride |
| Vilazodone hydrochloride (USAN) |
| Vilazodone hydrochloride [USAN] |
| Vilazodone hydrochloride solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material |
| Vilazodone hydrochloride, >=98% (HPLC) |
| vilazodone monohydrochloride |
| Vilazodonei |
Paragraph IV (Patent) Challenges for VIIBRYD
| Tradename | Dosage | Ingredient | NDA | Submissiondate |
|---|---|---|---|---|
| VIIBRYD | TABLET;ORAL | vilazodone hydrochloride | 022567 | 2015-01-21 |
US Patents and Regulatory Information for VIIBRYD
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Allergan Sales Llc | VIIBRYD | vilazodone hydrochloride | TABLET;ORAL | 022567-001 | Jan 21, 2011 | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | Start Trial | ||
| Allergan Sales Llc | VIIBRYD | vilazodone hydrochloride | TABLET;ORAL | 022567-002 | Jan 21, 2011 | RX | Yes | No | Start Trial | Start Trial | Y | Y | Start Trial | ||
| Allergan Sales Llc | VIIBRYD | vilazodone hydrochloride | TABLET;ORAL | 022567-001 | Jan 21, 2011 | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for VIIBRYD
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Allergan Sales Llc | VIIBRYD | vilazodone hydrochloride | TABLET;ORAL | 022567-001 | Jan 21, 2011 | Start Trial | Start Trial |
| Allergan Sales Llc | VIIBRYD | vilazodone hydrochloride | TABLET;ORAL | 022567-003 | Jan 21, 2011 | Start Trial | Start Trial |
| Allergan Sales Llc | VIIBRYD | vilazodone hydrochloride | TABLET;ORAL | 022567-002 | Jan 21, 2011 | Start Trial | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for VIIBRYD
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Slovakia | 162004 | Start Trial |
| China | 101139345 | Start Trial |
| Canada | 2782857 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
